Daily FNArena News

After delivering a record year, growth remains in Maas Group’s line of sight, with the market anticipating both organic growth and acquisitions in the year ahead

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Supply chain constraints have not hampered Data#3’s ability to deliver another record year, with the company describing constraint-driven backlog as a timing issue that will benefit FY23

Michael Gable of Fairmont Equities notes Woodside Energy has broken to the upside following a consolidation phase.

Boutique Australian and global active fund manager Alphinity spent six months meeting with portfolio managers to assess the state of the global economy

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Telix Pharmaceuticals’ prostate cancer imaging product Illucix is quickly conquering the USA, but management at the firm has (much) higher ambitions

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

A strong finish to the year looks to provide Corporate Travel Management with momentum as it moves into the new year, and should see the company benefit as markets reopen

Following FY22 results for Brambles, brokers set higher price targets following good cost control and higher pricing, though free cash flow concerns weigh